The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2026

Conditions

Empagliflozin in Cardiorenal Syndrome Type 1

Interventions

DRUG

Empagliflozin 10 MG

DRUG

Placebo

Matching placebo containing Lactose content (0.26 gram)

Trial Locations (1)

RECRUITING

Faculty of Medicine, Chulalongkorn University, Bangkok

All Listed Sponsors

lead

Chulalongkorn University

OTHER